Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)

Next Previous
Trial Profile

Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary) ; Pertuzumab (Primary) ; Tamoxifen (Primary) ; Trastuzumab (Primary) ; Aromatase inhibitors
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Results (n=35) assessing Pathologic examination of specimen after vacuum-assisted biopsy (VAB) in patients with breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 14 Jun 2022 Planned End Date changed from 10 Oct 2021 to 10 Dec 2028.
  • 14 Jun 2022 Planned primary completion date changed from 10 Oct 2021 to 10 Dec 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top